As pregnancies frequently occur in patients with IBD, and given that TNF inhibitors are increasingly being used for treatment of this chronic intestinal disease, the discontinuation of biologic agents during the third trimester in patients with quiescent disease has been advocated owing to safety concerns.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Safety of TNF-α inhibitors during IBD pregnancy: a systematic review
BMC Medicine Open Access 31 July 2013
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Cornish, J. et al. A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut 56, 830–837 (2007).
Zelinkova, Z. et al. Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure. Clin. Gastroenterol. Hepatol. http://dx.doi.org/10.1016/j.cgh.2012.10.024.
Dominitz, J. A., Young, J. C. & Boyko, E. J. Outcomes of infants born to mothers with inflammatory bowel disease: a population-based cohort study. Am. J. Gastroenterol. 97, 641–648 (2002).
Reddy, D., Murphy, S. J., Kane, S. V., Present, D. H. & Kornbluth, A. A. Relapses of inflammatory bowel disease during pregnancy: in-hospital management and birth outcomes. Am. J. Gastroenterol. 103, 1203–1209 (2008).
Singh, S., Sedgh, G. & Hussain, R. Unintended pregnancy: worldwide levels, trends, and outcomes. Stud. Fam. Plann. 41, 241–250 (2010).
Habal, F. M. & Huang, V. W. Review article: a decision-making algorithm for the management of pregnancy in the inflammatory bowel disease patient. Aliment. Pharmacol. Ther. 35, 501–515 (2012).
Zelinkova, Z. et al. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Aliment. Pharmacol. Ther. 33, 1053–1058 (2011).
Mahadevan, U. et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics. Am. J. Gastroenterol. 106, 214–223 (2011).
Mahadevan, U. et al. PIANO: a 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy [abstract]. Gastroenterology 142 (Suppl. 5), S-149 (2012).
Ben-Horin, S. et al. Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease. J. Crohns Colitis 5, 555–558 (2011).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Nielsen, O., Jess, T. Can TNF inhibitors be administered during the third trimester?. Nat Rev Gastroenterol Hepatol 10, 130–131 (2013). https://doi.org/10.1038/nrgastro.2012.248
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2012.248
This article is cited by
-
IBD medications during pregnancy and lactation
Nature Reviews Gastroenterology & Hepatology (2014)
-
Safety of TNF-α inhibitors during IBD pregnancy: a systematic review
BMC Medicine (2013)